A renowned physician, inventor, and biomedical entrepreneur with more than 30 years of experience in drug discovery and development, Dr. Andrew Salzman is an alumnus of Harvard Medical School, Yale University, and Columbia University. His professional achievements include:
- Publishing over 170 research papers
- Being cited in over 12,000 peer-reviewed papers
- Raising over $165M in NIH grants for research
- Obtaining over 60 patents
Dr. Salzman’s invention and development of the original clinical stage PARP-1 inhibitor led to the world’s first clinical treatment by increasing NAD levels and treating cancer caused by BRCA1 and BRCA2 genes. Genentech licensed his breakthrough technology in revamping human DNA for $600M. Dr. Salzman is renowned for his discoveries in gastrointestinal microbiota, including gut microbiomes, autoimmune disease, and mechanisms of pro-inflammatory gene expression.
Currently, Dr. Salzman serves as the Chief Medical Officer at Wonderfeel Biosciences, where he developed the formula for Youngr™ NMN. This innovative formula reflects his commitment to advancing wellness by optimizing cellular functions and healthy aging.
Today, Dr. Salzman’s work continues to benefit millions worldwide, as his research and drug development efforts have laid a foundation for treatments that address essential aspects of human health.
